Graves disease in infancy: a patient presentation and literature review

Kara Alex-Ann Beliard1, Srinidhi Shyamkumar2, Preneet Cheema Brar3

  • 1Icahn School of Medicine, Mount Sinai Department of Pediatric Endocrinology, Kravis Children's Hospital, New York, NY, USA.

Insights

This case study details the youngest infant diagnosed with Graves disease, a form of hyperthyroidism. Early diagnosis and treatment led to a full recovery, highlighting the importance of considering this condition in infants.

Area of Science:

  • Pediatrics
  • Endocrinology
  • Neonatology

Background:

  • Hyperthyroidism, an overactive thyroid, can present in infancy with symptoms like poor weight gain and a hyperdynamic state.
  • Autoimmune conditions are increasingly recognized in infants, necessitating broader diagnostic considerations.

Purpose of the Study:

  • To report the youngest documented case of Graves disease in an infant.
  • To emphasize the importance of early diagnosis and management of infantile hyperthyroidism.

Main Methods:

  • Case report of a 12-month-old infant presenting with symptoms suggestive of hyperthyroidism.
  • Biochemical confirmation of hyperthyroidism with positive thyroid-stimulating immunoglobulin.
  • Treatment with methimazole and propranolol.

Main Results:

  • The infant exhibited tachycardia, hypertension, diaphoresis, poor weight gain, and sleep difficulties.
  • Biochemical tests confirmed hyperthyroidism.
  • The patient showed a remarkable recovery following treatment with methimazole and propranolol.

Conclusions:

  • Graves disease can occur in infancy and should be considered in infants with poor weight gain and hyperdynamic symptoms.
  • Prompt diagnosis and treatment are crucial for managing infantile hyperthyroidism and preventing complications like craniosynostosis and growth abnormalities.
Abstract

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
49
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.2K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
215
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.6K
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
661
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
48